Skip to main content
Year archive

Diasorin — 2020 filings

All 117 regulatory filings released by Diasorin (DIA) in 2020, sourced directly from the official regulator.

117 Filings
2020 Period
2020 filings (117)
Filing Released Lang
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance
Regulatory Filings
2020-12-29 English
DiaSorin ha ricevuto un finanziamento dal governo americano per richiedere la certificazione 510(k) del test molecolare SIMPLEXA COVID-19 Direct
Regulatory Filings
2020-12-29 Italian
Comunicazione ammontare complessivo diritti di voto
Declaration of Voting Results & Voting Rights Announcements
2020-12-07 Italian
Communication on total amount of voting rights
Declaration of Voting Results & Voting Rights Announcements
2020-12-07 English
DiaSorin S.p.A. - Allegato 3F
Director's Dealing
2020-12-04 Italian
DiaSorin received FDA approval for its LIAISON XL MUREX HIV Ab/Ag assay
Regulatory Filings
2020-12-01 English
DiaSorin ha ricevuto l’approvazione a commercializzare il test LIAISON XL MUREX HIV Ab/Ag dalla Food and Drug Administration
Regulatory Filings
2020-12-01 Italian
DiaSorin: North America growth drives up revenues and profitability in the first 9 months of 2020
Interim / Quarterly Report 9M 2020
2020-11-11 English
DiaSorin: la crescita del Nord America traina l’aumento di Ricavi e Redditività nei primi 9 mesi del 2020
Interim / Quarterly Report 9M 2020
2020-11-11 Italian
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients
Regulatory Filings
2020-10-30 English
DiaSorin lancia con marcatura CE il LIAISON® SARS-CoV-2 Ag per la rilevazione dell’antigene SARS-CoV-2 in pazienti sintomatici
Regulatory Filings
2020-10-26 Italian
Conclusion treasury shares buy-back plan
Transaction in Own Shares
2020-10-23 English
Conclusione programma acquisto azioni proprie
Transaction in Own Shares
2020-10-23 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-10-23 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-10-23 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-10-16 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-10-16 Italian
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market
Regulatory Filings
2020-10-01 English
DiaSorin ha ricevuto l’approvazione a commercializzare 6 test per l’epatite B dalla Food and Drug Administration americana
Regulatory Filings
2020-10-01 Italian
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market
Regulatory Filings
2020-10-01 English
DiaSorin riceve l’approvazione ad uso di emergenza dalla Food and Drug Administration americana per il test LIAISON SARS-CoV-2 IgM negli Stati Uniti
Regulatory Filings
2020-10-01 Italian
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China
Regulatory Filings
2020-09-23 English
DiaSorin estende l’attuale joint-venture con il Governo cinese per l’apertura del nuovo impianto produttivo e di ricerca in Cina
Regulatory Filings
2020-09-23 Italian
Update Annual Calendar of Corporate Events 2020
Report Publication Announcement
2020-09-16 English
Aggiornamento Calendario Annuale Eventi Societari 2020
Regulatory Filings
2020-09-16 Italian
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens
Regulatory Filings
2020-09-16 English
DiaSorin ha posto la marcatura CE al proprio test Simplexa™ COVID-19 Direct per il suo utilizzo con campioni di saliva
Regulatory Filings
2020-09-16 Italian
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution
Regulatory Filings
2020-09-08 English
DiaSorin e MeMed avviano una partnership strategica per lo sviluppo e la commercializzazione di una soluzione diagnostica
Regulatory Filings
2020-09-08 Italian
DiaSorin receives FDA clearance for the SIMPLEXA™ Flu A/B & RSV Direct Gen II Assay
Regulatory Filings
2020-09-07 English
DiaSorin riceve l’approvazione dalla Food And Drug Administration per commercializzare negli Stati Uniti il nuovo test SIMPLEXA FLU A/B & RSV Direct
Regulatory Filings
2020-09-07 Italian
DiaSorin S.p.A. - Allegato 3F
Director's Dealing
2020-09-03 Italian
Half-Year Financial Report at June 30, 2020
Interim / Quarterly Report H1 2020
2020-08-14 English
Comunicato Internal Dealing
Director's Dealing
2020-08-10 Italian
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone
Regulatory Filings
2020-08-06 English
DiaSorin lancia il test LIAISON Testosterone xt con marcatura CE per il dosaggio del testosterone
Regulatory Filings
2020-08-06 Italian
Notice availability Half-Year Financial Report
Report Publication Announcement H1 2020
2020-08-03 English
Avviso disponibilità Relazione Finanziaria Semestrale
Report Publication Announcement
2020-08-03 Italian
Relazione Finanziaria Semestrale al 30 giugno 2020
Interim / Quarterly Report H1 2020
2020-08-03 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-07-31 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-07-31 Italian
DiaSorin - North America business growth drives Group revenues and profitability in the first half of 2020
Interim / Quarterly Report H1 2020
2020-07-30 English
DiaSorin - La crescita del business in Nord America spinge ricavi e redditività del Gruppo nel 1° semestre 2020
Interim / Quarterly Report H1 2020
2020-07-30 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-07-24 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-07-24 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-07-17 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-07-17 Italian
Shareholders' Meeting minutes June 10, 2020
AGM Information
2020-07-15 English
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-07-10 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-07-10 Italian
Notice availability Shareholders' meeting minutes June 10, 2020
Report Publication Announcement
2020-07-10 English
Avviso disponibilita' verbale Assemblea degli Azionisti 10 giugno 2020
Report Publication Announcement
2020-07-10 Italian
Verbale Assemblea degli Azionisti 10 giugno 2020
AGM Information
2020-07-10 Italian
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study
Regulatory Filings
2020-07-09 English
DiaSorin fornirà al Regno Unito il test sierologico LIAISON SARS-CoV-2 S1/S2 IgG per il completamento di uno screening della popolazione
Environmental & Social Information
2020-07-09 Italian
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay
Regulatory Filings
2020-07-07 English
DiaSorin lancia il nuovo test Simplexa Flu A/B & RSV Direct Gen II marcato CE, eseguibile in combinazione con il test Simplexa COVID-19 Direct
Regulatory Filings
2020-07-07 Italian
DiaSorin announces the launch of its new LIAISON SARS-COV-2 IgM test, a new fully automated serology kit
Regulatory Filings
2020-06-30 English
DiaSorin lancia il LIAISON SARS-CoV-2 IgM in Europa e negli Stati Uniti, un nuovo test sierologico automatizzato
Regulatory Filings
2020-06-30 Italian
Weekly report treasury shares buy-back
Transaction in Own Shares
2020-06-19 English
Informativa settimanale acquisto azioni proprie
Transaction in Own Shares
2020-06-19 Italian
Start up of treasury shares buy-back plan
Transaction in Own Shares
2020-06-17 English
Avvio programma di acquisto azioni proprie
Transaction in Own Shares
2020-06-17 Italian
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay
Regulatory Filings
2020-06-12 English
DiaSorin ha marcato CE il proprio test molecolare Simplexa™ Congenital CMV Direct
Regulatory Filings
2020-06-12 Italian
Shareholders' Meeting June 10, 2020
AGM Information
2020-06-10 English
Assemblea degli Azionisti 10 giugno 2020
AGM Information
2020-06-10 Italian
The LIAISON® SARS-CoV-2 S1 S2 IgG test receives the approval from ANVISA in Brazil
Regulatory Filings
2020-06-03 English
Il test sierologico LIAISON® SARS-CoV-2 S1 S2 IgG riceve l'approvazione da ANVISA per il mercato brasiliano
Regulatory Filings
2020-06-03 Portuguese
Communication voting rights amount
Declaration of Voting Results & Voting Rights Announcements
2020-06-02 English
Comunicazione ammontare complessivo diritti di voto
Declaration of Voting Results & Voting Rights Announcements
2020-06-02 Italian
DIASORIN - THE LIAISON® SARS-COV-2 S1S2 IGG TEST IS THE FIRST TO RECEIVE THE APPROVAL FROM HEALTH CANADA
Regulatory Filings
2020-05-18 English
DIASORIN - IL TEST SIEROLOGICO LIAISON® SARS-COV-2 S1S2 IGG È IL PRIMO A RICEVERE L’APPROVAZIONE DA HEALTH CANADA
Regulatory Filings
2020-05-18 Italian
DiaSorin - Q1 2020 results
Interim / Quarterly Report Q1 2020
2020-05-13 English
Risultati DiaSorin - Q1 2020
Earnings Release Q1 2020
2020-05-13 Italian
Report on the Remuneration Policy and fees paid 2019
Remuneration Information
2020-05-11 English
DiaSorin S.p.A - Shareholders' Meeting June 10, 2020 - Explanatory reports and motions for resolutions
AGM Information
2020-05-11 English
Relazione sulla Politica di Remunerazione e sui compensi corrisposti Esercizio 2019
Remuneration Information
2020-05-11 Italian
DiaSorin S.p.A. - Assemblea degli Azionisti 10 giugno 2020 - Relazioni illustrative e proposte di delibera
AGM Information
2020-05-11 Italian
DiaSorin S.p.A. - Shareholders' Meeting June 10, 2020 - Notice to call
AGM Information
2020-05-11 English
DiaSorin S.p.A. - Assemblea degli Azionisti 10 giugno 2020 - Avviso di convocazione
AGM Information
2020-05-11 Italian
Annual Report at December 31, 2019 (dividend dates update)
Annual Report FY 2019
2020-05-08 English
Relazione Finanziaria Annuale al 31 dicembre 2019 (aggiornamento date dividendo)
Annual Report FY 2019
2020-05-08 Italian
Notice re: Annual Report
Report Publication Announcement
2020-05-08 English
Avviso Relazione Finanziaria Annuale
Report Publication Announcement
2020-05-08 Italian
DiaSorin S.p.A.-Annual Financial Report at December 31, 2019
Annual Report FY 2019
2020-05-05 English
Notice of availability Annual Report
Report Publication Announcement
2020-04-29 English
Avviso disponibilita' Relazione Finanziaria Annuale
Report Publication Announcement
2020-04-29 Italian
DiaSorin S.p.A.-Relazione Finanziaria Annuale al 31 dicembre 2019
Annual Report FY 2019
2020-04-29 Italian
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG
Regulatory Filings
2020-04-25 English
DiaSorin riceve l'EUA dalla FDA americana sul test LIAISON® SARS-COV-2 S1/S2 IGG
Regulatory Filings
2020-04-25 Italian
Comunicato Internal Dealing
Director's Dealing
2020-04-22 Italian
Comunicato Internal Dealing
Director's Dealing
2020-04-22 Italian
Comunicato Internal Dealing
Director's Dealing
2020-04-22 Italian
DIASORIN HAS CE MARKED ITS SARS-COV-2 IGG SEROLOGY KIT FOR COVID-19
Regulatory Filings
2020-04-17 English
DIASORIN HA MARCATO CE IL PROPRIO TEST SIEROLOGICO SARS-COV-2 IGG PER IL COVID-19
Regulatory Filings
2020-04-17 Italian
Comunicato Internal Dealing
Director's Dealing
2020-04-16 Italian
Launch of IgG test to detect immune response to SARS-COV-2
Regulatory Filings
2020-04-07 English
Lancio test IgG per identificare risposta immunitaria al SARS-COV-2
Regulatory Filings
2020-04-07 Italian
Update Annual Calendar of Corporate Events 2020
Report Publication Announcement
2020-03-26 English
Aggiornamento Calendario Annuale Eventi Societari 2020
Regulatory Filings
2020-03-26 Italian
DiaSorin S.p.A. Shareholders' Meeting date change
AGM Information
2020-03-21 English
Variazione data Assemblea degli Azionisti DiaSorin S.p.A.
AGM Information
2020-03-21 Italian
DIASORIN COVID-19 TEST HAS RECEIVED FDA EMERGENCY USE AUTHORIZATION
Regulatory Filings
2020-03-20 English
DIASORIN - APPROVAZIONE FDA EUA TEST COVID-19 NEGLI USA
Regulatory Filings
2020-03-20 Italian
DiaSorin received BARDA funding to develop a rapid COVID-19 test
Regulatory Filings
2020-03-13 English
DiaSorin riceve finanziamento dal Governo Americano per lo sviluppo del test per il Coronavirus
Regulatory Filings
2020-03-13 Italian
DiaSorin - Cash flow generation and net profit hit record highs in 2019
Earnings Release FY 2019
2020-03-11 English
DiaSorin - Generazione di cassa ed utile netto record nel 2019
Earnings Release FY 2019
2020-03-11 Italian
DiaSorin - Development of Coronavirus test
Regulatory Filings
2020-03-10 English
DiaSorin avvia sviluppo test per Coronavirus
Regulatory Filings
2020-03-10 Italian
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology
Regulatory Filings
2020-03-02 English
DiaSorin sigla un accordo di licenza esclusiva con TTP per lo sviluppo di una soluzione molecclare Point-Of-Care
M&A Activity
2020-03-02 Italian
DiaSorin S.p.A.-Communication on total amount of voting rights
Declaration of Voting Results & Voting Rights Announcements
2020-02-07 English
DiaSorin S.p.A.-Comunicazione ammontare complessivo diritti di voto
Declaration of Voting Results & Voting Rights Announcements
2020-02-07 Italian
Annual Calendar of Corporate Events 2020
Regulatory Filings
2020-01-15 English
Calendario Annuale Eventi Societari 2020
Report Publication Announcement
2020-01-15 Italian